2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
130 recruiting
4
Rare Diseases
across 9 areas
0
News (30d)
Quiet
ReoStem L.L.C. is a company with 2 orphan drug designations across 4 rare diseases. 6 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Duchenne muscular dystrophy | Pre-Morula Stem Cells | Des.TrialAppr. |
| malignant carotid body paraganglioma | Pre-Morula Stem Cells | Des.TrialAppr. |
| post-treatment Lyme disease syndrome | Pre-Morula Stem Cells | Des.TrialAppr. |
| treatment-refractory schizophrenia | Pre-Morula Stem Cells | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
6
affecting portfolio
0% of portfolio targets high unmet need diseases
83
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
6
affecting portfolio